



**MANAGING POST-MEAL
GLUCOSE SPIKES
FOR A **HEALTHIER TOMORROW****

In T2DM for Quick Control of PPBG spike

Rx Diet, Exercise &

REP VOG®

Voglibose 0.2 mg + Repaglinide 0.5/1 mg Tablets
Voglibose 0.3 mg + Repaglinide 0.5/1/2 mg Tablets

**0.2/0.5
0.2/1
0.3/0.5
0.3/1
0.3/2**



In T2DM with Increased Postprandial Glycaemia

Rx Diet, Exercise &

MLRepa® **0.5
1
2**
Repaglinide 0.5/1/2 mg Tablets



In T2DM for Quick Control of PPBG spike



In T2DM with Increased Postprandial Glycaemia



Background:

Post-meal glucose spikes are a major challenge for individuals with Type 2 Diabetes, significantly increasing the risk of complications such as cardiovascular disease, kidney damage or other complications. These spikes occur when blood glucose levels rise sharply after eating, which can worsen overall glucose control and contribute to long-term health issues. Effective management of post-meal glucose spikes is essential to improve overall diabetes control and reduce the risk of complications.

The combination of Repaglinide, a quick-acting insulin secretagogue, and Voglibose, an alpha-glucosidase inhibitor, offers an effective dual-action approach for controlling postprandial blood glucose levels. Repaglinide stimulates quick insulin release, while Voglibose slows the absorption of glucose from the intestines. Together, they help prevent sharp glucose increases after meals, providing better control of postprandial glucose.

Repaglinide is safe in patients with mild to moderate renal impairment, but dosage adjustments are recommended in those with severe renal dysfunction to prevent the risk of prolonged insulin action.

Available Strengths

- Repvog (Repaglinide + Voglibose Combination Tablets)
- MLRepa (Repaglinide Tablets)

Indication:

Repvog is indicated for Quick control of postprandial blood glucose spike in patients with Type 2 Diabetes.

Mechanism of Action:

- Repaglinide stimulates the pancreas to release insulin quickly in response to meals, reducing post-meal glucose spikes.
- Voglibose inhibits the breakdown of carbohydrates in the intestines, slowing glucose absorption and preventing blood sugar spikes.

Dosage:

1 tablet before each major meal or as prescribed by the doctor.

Unique Selling Points (USP):

- Dual Action: Combines the fast insulin release of Repaglinide and the slow carbohydrate absorption effect of Voglibose for comprehensive post-meal glucose control.
- Quick and Sustained Control: Provides immediate glucose regulation while ensuring prolonged control through reduced carbohydrate absorption.
- Improved Diabetes Management: Helps lower post-meal glucose levels and reduces the risk of long-term complications.



Corp. & Regd. Office:

1009-1010, Chiranjiv Tower, 43, Nehru Place, New Delhi - 110019 Tel.: 011-47589500-51(50 lines)

Web: www.medicamen.com/lifesciences | E-mail: info@medicamenlifesciences.com



2025 All rights reserved, Medicamen Lifesciences Pvt Ltd